About TriSalus Life Sciences, Inc.
https://trisaluslifesci.comTriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
CEO
Mary T. Szela B.S.N.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:2.04M
Value:$11.89M
AWM INVESTMENT COMPANY, INC.
Shares:1.25M
Value:$7.29M
VANGUARD GROUP INC
Shares:1.16M
Value:$6.76M
Summary
Showing Top 3 of 57
About TriSalus Life Sciences, Inc.
https://trisaluslifesci.comTriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.57M ▲ | $18.67M ▲ | $-10.81M ▼ | -93.47% ▼ | $-0.96 ▼ | $-9.18M ▼ |
| Q2-2025 | $11.21M ▲ | $16.74M ▲ | $-8.29M ▲ | -73.91% ▲ | $-0.27 ▲ | $-6.7M ▲ |
| Q1-2025 | $9.17M ▲ | $15M ▲ | $-10.38M ▼ | -113.18% ▲ | $-0.39 ▲ | $-8.99M ▼ |
| Q4-2024 | $8.26M ▲ | $14.63M ▼ | $-10.11M ▼ | -122.36% ▼ | $-0.41 ▼ | $-8.85M ▼ |
| Q3-2024 | $7.35M | $15.08M | $-2.4M | -32.64% | $-0.12 | $-1.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $22.69M ▼ | $36.46M ▼ | $63.19M ▲ | $-26.73M ▼ |
| Q2-2025 | $26.49M ▲ | $41.32M ▲ | $60.74M ▼ | $-19.42M ▲ |
| Q1-2025 | $13M ▲ | $28.63M ▲ | $62.99M ▲ | $-34.37M ▼ |
| Q4-2024 | $8.53M ▼ | $23.97M ▼ | $49.87M ▲ | $-25.89M ▼ |
| Q3-2024 | $11.29M | $27.48M | $47.91M | $-20.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.81M ▼ | $-3.71M ▲ | $-176K ▼ | $82K ▼ | $-3.8M ▼ | $-3.92M ▲ |
| Q2-2025 | $-8.29M ▲ | $-7.32M ▼ | $93K ▲ | $20.72M ▲ | $13.49M ▲ | $-7.23M ▼ |
| Q1-2025 | $-10.38M ▼ | $-4.5M ▲ | $-714K ▼ | $9.69M ▲ | $4.47M ▲ | $-5.25M ▲ |
| Q4-2024 | $-10.11M ▼ | $-5.71M ▲ | $-50K ▲ | $2.99M ▼ | $-2.76M ▲ | $-5.76M ▲ |
| Q3-2024 | $-2.4M | $-10.85M | $-169K | $5.82M | $-5.19M | $-11.02M |
CEO
Mary T. Szela B.S.N.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:2.04M
Value:$11.89M
AWM INVESTMENT COMPANY, INC.
Shares:1.25M
Value:$7.29M
VANGUARD GROUP INC
Shares:1.16M
Value:$6.76M
Summary
Showing Top 3 of 57